E-GEOD-51131 - Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating precision medicine (PMed) trials
Released on 28 April 2014, last updated on 6 May 2014
Feasibility trial to examine the ability to conduct molecular guided therapy in a geographically distributed systems within strict time constraints Canine patients were enrolled across a broad panel of tumor types where tumor samples were acquired and processed to preserve RNA quality for genomic analysis at distributed locations to predict possible effective therapies. Genomic driven therapy suggestion derived using a collection of algorithms based on tumor expression levels.
transcription profiling by array
David Cherba <firstname.lastname@example.org>, Barbara Davis, Barbara Kitchell, Brad Charles, Chand Khanna1, Christina Mazcko, Christopher Kingsley, Craig Webb, David Vail, E.J. Ehrhart, Heather Fehling, Jeffrey Trent, Leena Kumar, Mark Neff, Melissa Paoloni, Michael Childress, Michael Henson, Seungchan Kim, Susan Lana
Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trials. Paoloni M, Webb C, Mazcko C, Cherba D, Hendricks W, Lana S, Ehrhart EJ, Charles B, Fehling H, Kumar L, Vail D, Henson M, Childress M, Kitchell B, Kingsley C, Kim S, Neff M, Davis B, Khanna C, Trent J. , Europe PMC 24637659